Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

被引：1
|
作者：
Moik, F. [1 ,2 ]
Riedl, J. M. [2 ]
Ay, C. [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Div Haematol & Haemostaseol, Vienna, Austria
[2] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 03期
关键词：
D O I：
10.1016/j.annonc.2023.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [31] Amivantamab plus chemotherapy vs chemotherapy as firstline treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
    Girard, N.
    Park, K.
    Tang, K.
    Cho, B. C.
    Paz-Ares, L.
    Cheng, S.
    Kitazono, S.
    Thiagarajan, M.
    Goldman, J. W.
    Sabari, J. K.
    Sanborn, R. E.
    Mansfield, A. S.
    Hung, J-Y.
    Popat, S.
    Dias, J.
    Bhattacharya, A.
    Agrawal, T.
    Shreeve, M.
    Knoblauch, R. E.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1304 - S1304
  • [32] BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study
    Elamin, Yasir Y.
    Nagasaka, Misako
    Shum, Elaine
    Bazhenova, Lyudmila
    Camidge, D. Ross
    Cho, Byoung Chul
    Felip, Enriqueta
    Goto, Koichi
    Lin, Chia-Chi
    Piotrowska, Zofia
    Planchard, David
    Rotow, Julia K.
    Spigel, David R.
    Tan, Daniel Shao-Weng
    Yoshida, Tatsuya
    Minchom, Anna Rachel
    De langen, Adrianus
    Kato, Terufumi
    Zalutskaya, Alena
    Reckamp, Karen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
    Yang, J. C-H.
    Ellers-Lenz, B.
    Straub, J.
    Johne, A.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
    Zhu, Viola Weijia
    Bestvina, Christine M.
    Lopes, Gilberto
    Hamm, John Turner
    Johnson, Melissa Lynne
    Lammers, Philip Edward
    Le, Xiuning
    Marathe, Omkar
    Raez, Luis E.
    Rao, Suman
    Sabari, Joshua K.
    Scheff, Ronald J.
    Tapan, Umit
    Thompson, Jonathan Robert
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Brutlach, Sabine
    Smit, Egbert F.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
    Lim, Sun Min
    Tan, Jiunn-Liang
    Dias, Josiane Mourao
    Voon, Pei Jye
    How, Soon Hin
    Zhou, Xiangdong
    Xiong, Hailin
    Massuti, Bartomeu
    Medley, Louise C.
    Nagasaka, Misako
    Vicente, David
    Girard, Nicolas
    Rittmeyer, Achim
    Botesteanu, Dana-Adriana
    Alhadab, Ali
    Mahoney, Janine M.
    Zhang, Jie
    Bauml, Joshua Michael
    Baig, Mahadi
    Scott, Susan Combs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
  • [36] Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC
    Kurata, Takayasu
    Nakagawa, Kazuhiko
    Satouchi, Miyako
    Seto, Takashi
    Sawada, Takeshi
    Han, Shi Rong
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nogami, Naoyuki
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study)
    Hata, A.
    Katakami, N.
    Nishino, K.
    Mori, M.
    Yokoyama, T.
    Kurata, T.
    Tachihara, M.
    Takase, N.
    Daga, H.
    Kijima, T.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Satouchi, M.
    Negoro, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
    Kim, S-W.
    Planchard, D.
    Feng, P-H.
    Karaseva, N.
    Kim, T. M.
    Lee, C. K.
    Poltoratskiy, A.
    Yanagitani, N.
    Powar, S.
    Huang, X.
    Howarth, P.
    Janne, P.
    Kobayashi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1382 - S1382
  • [40] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Yu, Helena
    Ahn, Myung-Ju
    Kim, Sang-We
    Cho, Byoung Chul
    Sequist, Lecia
    Orlov, Sergey
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Han, Ji-Youn
    CANCER RESEARCH, 2019, 79 (13)
12345